NCT07174570View on ClinicalTrials.gov

Celecoxib, Durvalaumab and Tremellimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 28, 2025

Primary Completion Date

November 13, 2025

Study Completion Date

November 13, 2026

Conditions
Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
DRUG

Celecoxib

Receive by mouth (PO).

BIOLOGICAL

Durvalumab

Receive intravenously (IV).

BIOLOGICAL

Tremelimumab

Given intravenously (IV).

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo Computed Tomography (CT).

PROCEDURE

Magnetic Resonance Imaging

Undergo Magnetic Resonance Imaging (MRI).

PROCEDURE

Biopsy Procedure

Undergo tissue biopsy.

Trial Locations (4)

30303

Grady Health System, Atlanta

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER

NCT07174570 - Celecoxib, Durvalaumab and Tremellimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer | Biotech Hunter | Biotech Hunter